Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Finished Goods (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Finished Goods data on record, last reported at $1.8 million in Q3 2025.

  • For Q3 2025, Finished Goods fell 33.09% year-over-year to $1.8 million; the TTM value through Sep 2025 reached $1.8 million, down 33.09%, while the annual FY2024 figure was $5.1 million, 31.58% down from the prior year.
  • Finished Goods reached $1.8 million in Q3 2025 per TNXP's latest filing, down from $2.4 million in the prior quarter.
  • Across five years, Finished Goods topped out at $7.5 million in Q4 2023 and bottomed at $1.8 million in Q3 2025.
  • Average Finished Goods over 3 years is $4.0 million, with a median of $3.7 million recorded in 2024.
  • Peak YoY movement for Finished Goods: tumbled 31.58% in 2024, then plummeted 33.09% in 2025.
  • A 3-year view of Finished Goods shows it stood at $7.5 million in 2023, then tumbled by 31.58% to $5.1 million in 2024, then plummeted by 65.63% to $1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $1.8 million in Q3 2025, $2.4 million in Q2 2025, and $4.8 million in Q1 2025.